Furthermore, as evidenced for CAR19 treatment of leukemia and as was also shown in an in vivo model of PSCA and MUC1-positive tumors [22], heterogeneous target antigen expression may lead to tumor escape variants when a single CAR T therapy is used. The gene discussed is MUC1; the disease is leukemia.